drugset / Trial / NCT05802862
A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to see if Insulin Degludec/Insulin Aspart (22011) compared to Insulin Degludec/Insulin Aspart (Ryzodeg) is similar in safety and effect in participants with type 2 diabetes (T2D).
Timeline
- Start
- 2023-07-06
- Primary completion
- 2024-08-16
- Completion
- 2024-08-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | insulin aspart | Protein / enzyme biologic | — | Subcutaneous |
| Subject | insulin degludec | Protein / enzyme biologic | — | Subcutaneous |